Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | CTSV | O60911 | 4/20 | 0.39 |
| ▸ | CTSL | P07711 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7820822 | 0.83 | ALDH1A1 (0.39) | KDM4EHPGDLMNAHSD17B10PARP1 | |
| SCHEMBL378547 | 0.76 | DNMT1 (0.38) | KDM4ELMNAHSD17B10PAX8PARP1 | |
| Hydrochloric Acid SCHEMBL28299257 | 0.75 | DNMT1 (0.37) | KDM4ELMNAHSD17B10PAX8PARP1 | |
| Hydrochloric Acid SCHEMBL6554454 | 0.75 | DNMT1 (0.37) | KDM4ELMNAHSD17B10PAX8PARP1 | |
| SCHEMBL11568940 | 0.73 | S100A4 (0.33) | KDM4EHPGDHSD17B10PARP1ALDH1A1 | |
| SCHEMBL1478085 | 0.72 | PARP1 (0.36) | HSD17B10PAX8PARP1ALDH1A1CES1 | |
| SCHEMBL5140067 | 0.71 | CES1 (0.38) | KDM4EHPGDLMNAHSD17B10PAX8 | |
| SCHEMBL6170258 | 0.69 | ALDH1A1 (0.34) | HPGDHSD17B10PARP1ALDH1A1ADORA2A | |
| SCHEMBL11773632 | 0.69 | ALOX5 (0.38) | KDM4EHPGDHSD17B10PARP1ALDH1A1 | |
| SCHEMBL1069945 | 0.69 | PARP1 (0.34) | PARP1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107082761-B | Phenanthridinone or benzophenanthridinone derivative and synthesis method thereof | 上海大学 | 2020-04-03 | — | — | CN | claimed |
| US-20250325600-A1 | Destroying Cancerous Cells Using Directed Bacteria | POSTREL RICHARD (US) | 2025-10-23 | — | — | US | disclosed |
| US-20230219895-A1 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | SHENZHEN XUHUA BIOTECH CO. LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| WO-2023081775-A1 | COMBINATION INHIBITORS FOR TREATING FIBROSIS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-114555189-A | Xanthophyllone derivatives as inhibitors of topoisomerase IB (TOP1) and/or tyrosyl-DNA phosphodiesterase 1(TDP1) | 美国政府健康及人类服务部 | 2022-05-27 | — | — | CN | disclosed |
| US-20210317115-A1 | INHIBITORS OF KIDNEY-TYPE GLUTAMINASE, GLS-1 | UNIV CORNELL (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210238633-A1 | System and Method for the Universal Destruction of Cancer Cells without Toxicity | POSTREL RICHARD (US) | 2021-08-05 | — | — | US | disclosed |
| US-11046945-B2 | Labeled glutaminase proteins, isolated glutaminase protein mutants, methods of use, and kit | CORNELL UNIVERSITY (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3826717-A2 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND/OR TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10987317-B2 | Inhibition of glutaminase C | CORNELL UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| US-20160002619-A1 | LABELED GLUTAMINASE PROTEINS, ISOLATED GLUTAMINASE PROTEIN MUTANTS, METHODS OF USE, AND KIT | CORNELL UNIVERSITY | 2016-01-07 | — | — | US | disclosed |
| WO-2014134329-A1 | LABELED GLUTAMINASE PROTEINS, ISOLATED GLUTAMINASE PROTEIN MUTANTS, METHODS OF USE, AND KIT | CORNELL UNIVERSITY (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20130252983-A1 | ACTIVATING PHOSPHORYLATION SITE ON GLUTAMINASE C | CORNELL UNIVERSITY (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120220610-A1 | INHIBITIONS OF GLUTAMINASE C | CORNELL UNIVERSITY (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012034123-A1 | ACTIVATING PHOSPHORYLATION SITE ON GLUTAMINASE C | CORNELL UNIVERSITY (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2010111504-A2 | INHIBITION OF GLUTAMINASE C | CORNELL UNIVERSITY (US) | 2010-09-30 | — | — | WO | disclosed |
| US-5395615-A | Free amine benzophenanthridine alkaloid compositions | VIPONT PHARMACEUTICAL, INC. (US) | 1995-03-07 | — | — | US | disclosed |
| EP-0583389-A1 | FREE AMINE BENZOPHENANTHRIDINE ALKALOID COMPOSITIONS | VIPONT PHARMACEUTICAL, INC. (US) | 1994-02-23 | — | — | EP | disclosed |
| US-5175000-A | Treating bacterial or fungal infections | VIPONT PHARMACEUTICAL, INC. (US) | 1992-12-29 | — | — | US | disclosed |
| WO-1992019242-A1 | FREE AMINE BENZOPHENANTHRIDINE ALKALOID COMPOSITIONS | VIPONT PHARMACEUTICAL, INC. (US) | 1992-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252983-A1 | ACTIVATING PHOSPHORYLATION SITE ON GLUTAMINASE C | GLS, GLUL, GLS2 | KDM4E 2854/4885CTSV 2527/4885CTSL 2136/4885 |
| US-20120220610-A1 | INHIBITIONS OF GLUTAMINASE C | GLS, GLS2, GLUL | KDM4E 1683/4885CTSV 722/4885CTSL 714/4885 |
| US-20230219895-A1 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | TDP1, TOP1, TOP2A | KDM4E 1070/4885CTSV 4597/4885CTSL 4269/4885 |
| US-20210317115-A1 | INHIBITORS OF KIDNEY-TYPE GLUTAMINASE, GLS-1 | GLS, GLS2, GLUL | KDM4E 1104/4885CTSV 1266/4885CTSL 1232/4885 |
| US-10987317-B2 | Inhibition of glutaminase C | GLS, GLS2, GLUL | KDM4E 1447/4885CTSV 695/4885CTSL 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.